tiprankstipranks
Trending News
More News >
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
US Market

ImmunoCellular Therapeutics (IMUC) Income Statement

Compare
184 Followers

ImmunoCellular Therapeutics Income Statement

Last quarter (Q4 2022), ImmunoCellular Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, ImmunoCellular Therapeutics's net income was $-464.52K. See ImmunoCellular Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 2.01M$ 1.82M$ 2.89M$ 2.61M$ 1.45M
Depreciation and Amortization
$ 0.00$ 167.90K$ 228.49K$ 2.61M$ 1.94M
EBITDA
$ -929.09K$ -999.29K$ -2.21M$ -1.00$ 0.00
Operating Income
$ -2.01M$ -1.65M$ -2.89M$ -2.61M$ -1.45M
Other Income/Expenses
$ 114.22K$ -63.70K$ 238.41K$ -65.71K$ 0.00
Pretax Income
$ -1.89M$ -1.72M$ -2.65M$ -2.68M$ -1.45M
Net Income
$ -1.89M$ -1.61M$ -2.65M$ -2.68M$ -1.45M
Per Share Metrics
Basic EPS
$ -0.02$ -0.01$ -0.02$ -0.06$ -0.03
Diluted EPS
$ -0.02$ -0.01$ -0.02$ -0.06$ -0.03
Weighted Average Shares Outstanding
115.10M 113.27M 113.27M 45.43M 45.08M
Weighted Average Shares Outstanding (Diluted)
115.10M 113.27M 113.27M 45.43M 45.08M
Currency in USD

ImmunoCellular Therapeutics Earnings and Revenue History